Omidenepag

Omidenepag
Clinical data
Trade names	Eybelis, Omlonti
Other names	UR-7276, DE-117, Omidenepag isopropyl (JAN JP)
Routes of; administration	Topical eye drops
ATC code	S01EX06 (WHO) ;
Legal status
Legal status	US: ℞-only; Rx-only;
Identifiers
	IUPAC name Propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate;
CAS Number	1187451-41-7; 1187451-19-9;
PubChem CID	44230575; 44230999;
DrugBank	DB15071;
ChemSpider	44210451; 57643658;
UNII	Z95F9F9LU4; G0G0H52U6K;
KEGG	D10965; D10966;
ChEMBL	ChEMBL3707245; ChEMBL4297666;
Chemical and physical data
Formula	C26H28N6O4S
Molar mass	520.61 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)OC(=O)CNC1=CC=CC(CN(CC2=CC=C(C=C2)N2C=CC=N2)S(=O)(=O)C2=CC=CN=C2)=N1;
	InChI InChI=1S/C23H22N6O4S/c30-23(31)15-25-22-6-1-4-19(27-22)17-28(34(32,33)21-5-2-11-24-14-21)16-18-7-9-20(10-8-18)29-13-3-12-26-29/h1-14H,15-17H2,(H,25,27)(H,30,31); Key:YHGSTSNEOJUIRN-UHFFFAOYSA-N; ; InChI=1S/C26H28N6O4S/c1-20(2)36-26(33)17-28-25-8-3-6-22(30-25)19-31(37(34,35)24-7-4-13-27-16-24)18-21-9-11-23(12-10-21)32-15-5-14-29-32/h3-16,20H,17-19H2,1-2H3,(H,28,30); Key:VIQCWEGEHRBLAC-UHFFFAOYSA-N;

Omidenepag, sold under the brand name Eybelis among others, is a medication used for the treatment of glaucoma and ocular hypertension.^[1]^[3]

Omidenepag was approved for medical use in Japan in 2018,^[3] and in the United States in September 2022.^[2]^[4]

Medical uses

Omidenepag is indicated for the treatment of glaucoma and ocular hypertension.^[1]^[3]

Adverse effects

The most common adverse effects of omidenepag are conjunctival hyperemia and macular edema, including cystoid macular edema.^[3]

Pharmacology

Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.^[5] Omidenepag is a selective prostaglandin E2 receptor agonist.^[6]^[7]

History

Omidenepag was developed by Ube Industries and Santen Pharmaceutical.^[3]

References

^ ^a ^b ^c "Omlonti- omidenepag isopropyl solution/ drops". DailyMed. 30 September 2022. Retrieved 16 October 2022.
^ ^a ^b "Drug Approval Package: Omlonti". U.S. Food and Drug Administration (FDA). 20 October 2022. Retrieved 4 December 2022.
^ ^a ^b ^c ^d ^e ^f Duggan S (December 2018). "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs. 78 (18): 1925–1929. doi:10.1007/s40265-018-1016-1. PMID 30465134. S2CID 53721056.
^ "Santen and UBE Received FDA Approval for Omlonti (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension" (Press release). Santen. 26 September 2022. Retrieved 1 October 2022 – via Business Wire.
^ "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico. Archived from the original on 8 January 2022. Retrieved 8 January 2022.
^ Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, et al. (January 2018). "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science. 59 (1): 145–153. doi:10.1167/iovs.17-22745. PMID 29332128.
^ Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H (September 2020). "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports. 10 (1): 16018. Bibcode:2020NatSR..1016018I. doi:10.1038/s41598-020-72538-x. PMC 7524797. PMID 32994409.

External links

"Omidenepag". Drug Information Portal. U.S. National Library of Medicine.
"Omidenepag isopropyl". Drug Information Portal. U.S. National Library of Medicine.
"Omidenepag". NCI Thesaurus.
"Omidenepag isopropyl". NCI Thesaurus.

[Omlonti_FDA_label-1] "Omlonti- omidenepag isopropyl solution/ drops". DailyMed. 30 September 2022. Retrieved 16 October 2022.

[Drug_Approval_Package:_Omlonti-2] "Drug Approval Package: Omlonti". U.S. Food and Drug Administration (FDA). 20 October 2022. Retrieved 4 December 2022.

[Duggan-3] ^ ^a ^b ^c ^d ^e ^f Duggan S (December 2018). "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs. 78 (18): 1925–1929. doi:10.1007/s40265-018-1016-1. PMID 30465134. S2CID 53721056.

[4] "Santen and UBE Received FDA Approval for Omlonti (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension" (Press release). Santen. 26 September 2022. Retrieved 1 October 2022 – via Business Wire.

[5] "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico. Archived from the original on 8 January 2022. Retrieved 8 January 2022.

[6] Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, et al. (January 2018). "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science. 59 (1): 145–153. doi:10.1167/iovs.17-22745. PMID 29332128.

[7] Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H (September 2020). "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports. 10 (1): 16018. Bibcode:2020NatSR..1016018I. doi:10.1038/s41598-020-72538-x. PMC 7524797. PMID 32994409.

[1]

[3]

[2]

[4]

[5]

[6]

[7]